dr. ku on role of durvalumab in gastric cancer
Published 5 years ago • 517 plays • Length 1:08Download video MP4
Download video MP3
Similar videos
-
0:56
dr. ku on immunotherapy for gastric and esophageal cancer
-
1:07
dr. balar on impact of durvalumab plus tremelimumab in bladder cancer
-
1:17
dr. arkenau on the potential of immunotherapy in gastric cancer
-
4:01
the role of immunotherapy in gastrointestinal cancers: an update from esmo
-
1:05
dr. sonpavde on the role of durvalumab in platinum-refractory bladder cancer
-
0:47
dr. feldman on durvalumab for patients with lung cancer
-
1:20
dr. simon on durvalumab for patients with lung cancer
-
1:35
dr. fakih on durvalumab and tremelimumab in crc
-
0:53
dr. siefker-radtke on fda approval of durvalumab in bladder cancer
-
2:10
dr. langer on the benefit of durvalumab in stage iii nsclc
-
6:06
stage iii nsclc: when to start durvalumab
-
1:42
dr. feldman on the future of durvalumab and tremilimumab in nsclc
-
1:10
dr. powles discusses the future of durvalumab in bladder cancer
-
3:53
[lung]the role of durvalumab in patients with stage 3 lung cancer in a real hospital
-
0:58
dr. davis on the potential for maintenance therapy in gastric cancer
-
1:08
dr. bazhenova on the pacific trial with durvalumab in nsclc
-
1:50
highlights on pcr to durvalumab flot in gastric and gej cancer: the matterhorn study
-
1:43
dr. sonpavde discusses a study of fixed-dose durvalumab and tremelimumab in urothelial carcinoma
-
1:03
dr. zandberg on durvalumab trial in head and neck cancer